---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-096703"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:53:22.966155+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio director Mark Iwicki to resign from board, effective Dec 31, 2025

## Summary
- Mark Iwicki notified his resignation from the board on April 25, 2025, effective December 31, 2025.
- He will remain Chair and Compensation Committee chair, and Audit Committee member until the effective date.
- Resignation is to reduce board commitments; no disagreement with the company.
- He will continue as CEO of Inhibikase Therapeutics, Inc.

## SEC filing metadata
- accession: 0001193125-25-096703
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312525096703/0001193125-25-096703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312525096703/d933973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-096703
- JSON: https://secwatch.observer/filing/0001193125-25-096703.json
- Plain text: https://secwatch.observer/filing/0001193125-25-096703.txt

## Key facts
- Executive change
  Mark Iwicki resigned as Director at Q32 Bio Inc..
  - Action: resigned
  - Role: Director
  source text: On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312525096703/0001193125-25-096703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.